Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.480.02%
QQQ
714.89-
BTC/USD
77281.400.0952%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Inhibikase Therapeutics Inc

IKTNASDAQ
Trade with Public
Trade with Public
$2.34
0.010.43%
At close: Sep 11, 5:00 PM EST
$2.34
N/A
After Hours: 4:01 PM EST
OverviewNewsEarnings ForecastPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Inhibikase Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inhibikase Therapeutics (IKT).

Price Target Range — 7 Quarters

Analyst Consensus — 7 Analysts

7Buy
Consensus RatingBuy# Analysts7Avg. Consensus PT$5Upside to Avg. PT+132.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 10, 2026Oppenheimer—InitiateOutperform$5
Mar 4, 2026Ladenburg ThalmannAydin HuseynovInitiateBuy$4
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On Inhibikase Therapeutics with Outperform Rating, Announces Price Target of $5

Oppenheimer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Outperform rating and announces Price Target of $5.
Benzinga Newsdesk

PRO
Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $6

B of A Securities analyst Jason Zemansky initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Inhibikase Therapeutics at Buy, Announces Price Target of $8

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $8.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Inhibikase Therapeutics with Overweight Rating, Announces Price Target of $4

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Overweight rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Inhibikase Therapeuticsto Neutral

HC Wainwright & Co. analyst Edward White reiterates Inhibikase Therapeutics (NASDAQ:IKT) from Neutral to Neutral.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved